Font Sizes: A A A

LIST OF PUBLICATIONS

PEER-REVIEWED PAPERS PUBLISHED IN INTERNATIONAL AND NATIONAL JOURNALS 

2017 (until August)

Number of publications: 33

Cumulative impact factor: 116,317

  1. Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr. 2017 Jan 6:1-11. IF: 3,589.
  2. Gyertyán I. Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets. Trends Pharmacol. Sci. 2017 Feb; 38 (2):113-126. IF: 12,797.
  3. Knoll J, Baghy K, Eckhardt S, Ferdinandy P, Garami M, Harsing LG, Hauser P, Mervai Z, Pocza T, Schaff Z, Schuler D, Miklya I. A longevitystudy with enhancer subatances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain. Life Sci. 2017 Aug 1; 182:57-64. IF: 2,936.
  4. Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS. Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model. Int J Neuropsychopharmacol. 2017 May 22. [Epub ahead of print] IF: 4,712.
  5. Varga B, Kassai F, Szabó G, Kovács P, Fischer J, Gyertyán I. Pharmacological comparison of traditional and non-traditional cannabinoid receptor 1 blockers in rodent models in vivo. Pharmacol Biochem Behav. 2017 Aug;159:24-35. IF: 2,748.
  6. Fehér Á, Tóth VE, Al-Khrasani M, Balogh M, Lázár B, Helyes Z, Gyires K, Zádori ZS. Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice. Inflammopharmacology.  2017 Feb; 25 (1):107-118. IF: 2,59.
  7. Gyires K, Fehér Á. Stress, neuropeptides and gastric mucosa. Curr Pharm Des. 2017 Apr 28. IF: 2,611.
  8. Zádor F, Király K, Váradi A, Balogh M, Fehér Á, Kocsis D, Erdei AI, Lackó E, Zádori ZS, Hosztafi S, Noszál B, Riba P, Benyhe S, Fürst S, Al-Khrasani M. New opioid receptor antagonist: naltrexone-14-O-sulfate synthesis and pharmacology. Eur J Pharmacol. 2017 Aug 15; 809:111-121. IF: 2,896.
  9. Andreadou I, Iliodromitis EK, Lazou A, Görbe A, Giricz Z, Schulz R, Ferdinandy P. Effect of hypercholesterolemia on myocardial function, ischemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol. 2017 Jun; 174 (12):1555-1569. IF: 5,491.
  10. Kalász H, Tekes K, Faigl EB, Pöstényi Z. Berekméri E, Karvaly G, Adeghate E. Monitoring the Level of 14C-Labelled Selegiline Following Oral Administration. Open Med Chem J.2017 Jan 31; 11:1-8. IF: 0.
  11. Nurulain SM, Ojha S, Dhanasekaran S, Kuca K, Nalin N, Sharma C, Adem A, Kalasz H. HPLC determination of K027 in the body of pregnant mice. Acta Chromatographica. 2017. 1, 85–93. IF: 0,755.
  12. Kalász H, Hunyadi A, Tekes K, Dolesal R, Karvaly G. HPLC Analysis and Blood–Brain Penetration of 20-Hydroxyecdysone Diacetonide. Acta Chromatographica. 2017. IF: 0,755.
  13. Brockhoff B, Schreckenberg R, Forst S, Heger J, Bencsik P, Kiss K, Ferdinandy P, Schulz R, Schlüter KD. Effect of nitric oxide deficiency on the pulmonary PTHrP system. J Cell Mol Med.2017 Jan; 21 (1):96-106. IF: 4,499.
  14. Baranyai T, Giricz Z, Giricz Z, Varga ZV, Koncsos G, Lukovic D, Makkos A, Sárközy M, Pávó N, Jakab A, Czimbalmos C, Vágó H, Ruzsa Z, Tóth L, Garamvölgyi R, Merkely B, Schulz R, Gyöngyösi M, Ferdinandy P. In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature. J Transl Med. 2017 Apr 1; 15(1):67. IF: 3,786.
  15. Hausenloy DJ, Garcia-Dorado D, Erik Bøtker H, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JP, Van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P. Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res.2017 May 1; 113 (6):564-585. IF: 5,878.
  16. Giricz Z, Koncsos G, Rajtík T, Varga ZV, Baranyai T, Csonka C, Szobi A, Adameová A, Gottlieb RA, Ferdinandy P. Hypercholesterolemia downregulates autophagy in the rat heart. Lipids Health Dis.2017 Mar 23; 16 (1):60. IF: 2,073.
  17. Pipicz M, Kocsis GF, Sárváry-Arantes L, Bencsik P, Varga ZV, Ferdinandy P, Csont T. Low-Dose Endotoxin Induces Late Preconditioning, Increases Peroxynitrite Formation, and Activates STAT3 in the Rat Heart. Molecules.2017 Mar 8; 22 (3). IF: 2,861.
  18. Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Jan Ankersmit H, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M. Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Sci Rep.2017 Mar 7;7:43958. IF: 4,259.
  19. Perrino C, Barabási AL, Condorelli G, Davidson SM, De Windt L, Dimmeler S, Engel FB, Hausenloy DJ, Hill JA, Van Laake LW, Lecour S, Leor J, Madonna R, Mayr M, Prunier F, Sluijter JP, Schulz R, Thum T, Ytrehus K, Ferdinandy P. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischemic heart? Cardiovasc Res. Cardiovasc Res.2017 Jun 1;113(7):725-736. IF: 5,878.
  20. Szobi A, Gonçalvesová E, Varga Z, Leszek P, Kuśmierczyk M, Hulman M, Kyselovič J, Ferdinandy P, Adameová A. Analysis of necroptotic proteins in failing human hearts. J Transl Med. 2017 May 11;15(1):103. IF: 3,786.
  21. Kerpel-Fronius S. A short review of the pharmacokinetic behavior of
    biological medicinal agents for the clinical practice. Microchem J. 2017. IF: 3,034.
  22. Egea J, Fabregat I, Frapart YM, Ghezzi P, Görlach A, Kietzmann T, Kubaichuk K, Knaus UG, Lopez MG, Olaso-Gonzalez G, Petry A, Schulz R, Vina J, Winyard P, Abbas K, Ademowo OS, Afonso CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertrán E, Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A, Chondrogianni N, Conrad M, Cooke MS, Costa JG, Cuadrado A, My-Chan Dang P, De Smet B, Debelec-Butuner B, Dias IHK, Dunn JD, Edson AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark KE, Förstermann U, Giniatullin R, Giricz Z, Görbe A, Griffiths H, Hampl V, Hanf A, Herget J, Hernansanz-Agustín P, Hillion M, Huang J, Ilikay S, Jansen-Dürr P, Jaquet V, Joles JA, Kalyanaraman B, Kaminskyy D, Karbaschi M, Kleanthous M, Klotz LO, Korac B, Korkmaz KS, Koziel R, Kračun D, Krause KH, Křen V, Krieg T, Laranjinha J, Lazou A, Li H, Martínez-Ruiz A, Matsui R, McBean GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milković L, Miranda-Vizuete A, Mojović M, Monsalve M, Mouthuy PA, Mulvey J, Münzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira NG, Palmeira CM, Papaevgeniou N, Pavićević A, Pedre B, Peyrot F, Phylactides M, Pircalabioru GG, Pitt AR, Poulsen HE, Prieto I, Rigobello MP, Robledinos-Antón N, Rodríguez-Mañas L, Rolo AP, Rousset F, Ruskovska T, Saraiva N, Sasson S, Schröder K, Semen K, Seredenina T, Shakirzyanova A, Smith GL, Soldati T, Sousa BC, Spickett CM, Stancic A, Stasia MJ, Steinbrenner H, Stepanić V, Steven S, Tokatlidis K, Tuncay E, Turan B, Ursini F, Vacek J, Vajnerova O, Valentová K, Van Breusegem F, Varisli L, Veal EA, Yalçın AS, Yelisyeyeva O, Žarković N, Zatloukalová M, Zielonka J, Touyz RM, Papapetropoulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber A. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biol.2017 May 18; 13:94-162. IF: 6,337.
  23. Bencsik P, Bartekova M, Görbe A, Kiss K, Pálóczi J, Radosinska J, Szűcs G, Ferdinandy P. MMP Activity Detection in Zymograms. Methods Mol Biol.2017;1626:53-70. IF: 0.
  24. Daiber A, Di Lisa F, Ferdinandy P. Pharmacology of oxidative stress: translational opportunities. Br J Pharmacol.2017 Jun; 174 (12):1511-1513. IF: 0.
  25. Pavo N, Lukovic D, Zlabinger K, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Ankersmit HJ, Giricz Z, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M. Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget.2017 Jun 12. IF: 5,168.
  26. Kemény Á, Csekő K, Szitter I, Varga ZV, Bencsik P, Kiss K, Halmosi R, Deres L, Erős K, Perkecz A, Kereskai L, László T, Kiss T, Ferdinandy P, Helyes Z. Integrative characterization of chronic cigarette smoke-induced cardiopulmonary comorbidities in a mouse model. Environ Pollut.2017 Jun 22. IF: 5,099.
  27. Jankovic A, Korac A, Buzadzic B, Stancic A, Otasevic V, Ferdinandy P, Daiber A, Korac B. Targeting the nitric oxide/superoxide ratio in adipose tissue: relevance in obesity and diabetes management. Br J Pharmacol. 2017 Jun; 174(12):1570-1590. IF: 5,491.
  28. Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: A mini review. Curr Diabetes Rev. 2017;13(1):3-10 IF: 3,387
  29. Benke K, Ágg B, Pólos M, Sayour AA, Radovits T, Bartha E, Nagy E, Rákóczi B, Koller Á, Szokolai V, Hedberg J, Merkely B, Nagy BZ and Szabolcs Z. “The effects of acute and elective cardiac surgery on the anxiety traits of patients with Marfan syndrome”. BMC Psychiatry. 2017 Jul 17; 17 (1):253. IF: 2,613.
  30. Giricz Z, Varga ZV, Koncsosa G, Nagy Cs, Görbe A, Mentzer Jrb RM, Gottliebb RA, Ferdinandy P. Autophagosome formation is required for cardioprotection by chloramphenicol. Life Sci. 2017 Aug 1. [Epub ahead of print] IF: 2,936.
  31. Csonka C, Baranyai T, Tiszlavicz L, Fébel H, Szűcs G, Varga ZV, Sárközy M, Puskás LG, Antal O, Siska A, Földesi I, Ferdinandy P, Czakó L, Csont T. Isolated hypercholesterolemia leads to steatosis in the liver without affecting the pancreas. Lipids Health Dis. 2017 Jul 27;16(1):144. IF: 2,073.
  32. Arshad M, Fatmi MQ, Musilek K, Hussain A, Kuca K, Petroianu G, Kalasz H, Nurulain SM. In silico and in vitro evaluation of two novel oximes (K378 and K727) in comparison to K-27 and pralidoxime against paraoxon-ethyl intoxication. Toxicol Mech Methods. 2017 Aug 4:1-7. [Epub ahead of print] IF: 1,595.
  33. Adeghate J, Nurulain S, Tekes K, Fehér E, Kalász H, Adeghate E. Novel biological therapies for the treatment of diabetic foot ulcers. Expert Opin Biol Ther. 2017 Aug;17(8):979-987. IF: 3,684.

 

2016

Number of publications: 32

Cumulative impact factor: 130,963

  1. Éliás E, Nógrádi K, Domány G, Szakács Z, Kóti J, Szántay C Jr, Tarcsay Á, Keserű GM, Gere A, Kiss B, Kurkó D, Kolok S, Némethy Z, Kapui Z, Hellinger É, Vastag M, Sághy K, Kedves R, Gyertyán I. The influence of 5-HT(2A) activity on a 5-HT(2C) specific in vivo assay used for early identification of multiple acting SERT and 5-HT(2C) receptor ligands. Bioorg Med Chem Lett. 2016 Feb 1; 26(3):914-20. IF: 2,454 .
  2. Miklya I. The significance of selegiline/(-) deprenyl after 50 years in research and therapy (1965-2015-). Mol. Psychiatr. 2016 Nov; 21(11):1499-1503. IF: 13,204.
  3. Lacko E, Riba P, Giricz Z, Varadi A, Cornic L, Balogh M, Kiraly K, Cseko K, Mousa SA, Hosztafi S, Schafer M, Zadori ZS, Helyes Z, Ferdinandy P, Furst S, Al-Khrasani M. New Morphine Analogs Produce Peripheral Antinociception within a Certain Dose Range of Their Systemic Administration. J Pharmacol Exp Ther. 2016 Oct; 359(1):171-81. IF: 3,867.
  4. Shakura M, “Li X, Al-Khrasani M, Shakibaei M, Tafelski S,Fürst S, Beyer A, Kawata M, Schafer M, Mousa S. A. “Membrane-bound glucocorticoid receptors on distinct nociceptive neurons as potential targets for pain control through rapid non-genomic effects”. Neuropharmacol. 2016 Dec; 111:1-13. IF: 5,012.
  5. Knoll J, Miklya I. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). Life Sci. 2016 Dec 15; 167:32-38. IF: 2,936.
  6. Zadori ZS, Feher A, Tóth VE, Al-Khrasani M, Koles L, Sipos S, Del Bello F, Pigini M, Gyires K. Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility. Dig Dis Sci. 2016 Jun; 61(6):1512-23. IF: 2,875.
  7. Horvath T, Polony G, Fekete A, Aller M, Halmos G, Lendvai B, Heinrich A, Sperlagh B, Vizi ES, Zelles T. ATP-Evoked Intracellular Ca2+ Signaling of Different Supporting Cells in the Hearing Mouse Hemicochlea. Neurochem Res. 2016 Feb; 41(1-2):364-75. IF: 2,581.
  8. Foldes A, Kadar K, Keremi B, Zsembery A, Gyires K, Zadori ZS, Varga G. Mesenchymal stem cells of dental origin – their potential for anti-inflammatory and regenerative actions in brain and gut damage. Curr Neuropharmacol. 2016 Jan 20; 14(8):914-934. IF: 3,365.
  9. Hanuska A, Szenasi G, Albert M, Koles L, Varga A, Szabo A, Matyus P, Harsing LG Jr. Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions. Neurochem Res. 2016 Feb; 41(1-2):73-85. IF: 2,581.
  10. Gyires K, Zadori Z. Role of cannabinoids in gastrointestinal mucosal defense and inflammation. Curr Neuropharmacol. 2016 Mar 2; 14(8):935-951. IF: 3,365.
  11. Koles L, Kato E, Hanuska A, Zadori ZS, Al-Khrasani M, Zelles T, Rubini P, Illes P. Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems. Purinergic Signal. 2016 Mar; 12(1):1-24. IF: 3,022.
  12. Zadori ZS, Toth VE, Feher A, Al-Khrasani M, Puskar Z, Kozsurek M, Timar J, Tabi T, Helyes Z, Hein L, Holzer P, Gyires K. Inhibition of α2A-Adrenoceptors Ameliorates Dextran Sulfate Sodium-Induced Acute Intestinal Inflammation in Mice. J Pharmacol Exp Ther. 2016 Sep; 358(3):483-91. IF: 3,867.
  13. Koványi B, Csölle C, Calovi S, Hanuska A, Kató E, Köles L, Bhattacharya A, Haller J, Sperlágh B. The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Sci Rep. 2016 Nov 8; 6:36680. IF: 4,259.
  14. Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016 Nov;111(6):70. IF: 5,306.
  15. Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. Pharmacol Res. 2016 Nov; 113(Pt A):62-70. IF: 4,48.
  16. Cabrera-Fuentes HA, Aragones J, Bernhagen J, Boening A, Boisvert WA, Bøtker HE, Bulluck H, Cook S, Di Lisa F, Engel FB, Engelmann B, Ferrazzi F, Ferdinandy P, Fong A, Fleming I, Gnaiger E, Hernández-Reséndiz S, Kalkhoran SB, Kim MH, Lecour S, Liehn EA, Marber MS, Mayr M, Miura T, Ong SB, Peter K, Sedding D, Singh MK, Suleiman MS, Schnittler HJ, Schulz R, Shim W, Tello D, Vogel CW, Walker M, Li QO, Yellon DM, Hausenloy DJ, Preissner KT. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”. Basic Res Cardiol. 2016 Nov;111(6):69. IF: 5,306.
  17. Koncsos G, Varga ZV, Baranyai T, Boengler K, Rohrbach S, Li L, Schlüter KD, Schreckenberg R, Radovits T, Oláh A, Mátyás C, Lux Á, Al-Khrasani M, Komlódi T, Bukosza N, Máthé D, Deres L, Barteková M, Rajtík T, Adameová A, Szigeti K, Hamar P, Helyes Z, Tretter L, Pacher P, Merkely B, Giricz Z, Schulz R, Ferdinandy P. Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol. 2016 Oct 1;311(4):H927-H943. IF: 3,348.
  18. Sárközy M, Szűcs G, Fekete V, Pipicz M, Éder K, Gáspár R, Sója A, Pipis J, Ferdinandy P, Csonka C, Csont T. Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats. Cardiovasc Diabetol. 2016 Aug 5; 15(1):110. IF: 4,752.
  19. Kiscsatari L, Varga Z, Schally AV, Gaspar R, Nagy CT, Giricz Z, Ferdinandy P, Fabian G, Kahan Z, Gorbe A. Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone. Pharmacol Res. 2016 Sep; 111:859-66. IF: 4,48.
  20. Paloczi J, Varga ZV, Apati A, Szebenyi K, Sarkadi B, Madonna R, De Caterina R, Csont T, Eschenhagen T, Ferdinandy P, Gorbe A. Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury. Oxid Med Cell Longev. 2016; 2016:4298945. IF: 4,593.
  21. Boros K, Jancso G, Dux M, Fekecs Z, Bencsik P, Oszlacs O, Katona M, Ferdinandy P, Nogradi A, Santha P. Multiple impairments of cutaneous nociceptor function induced by cardiotoxic doses of Adriamycin in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2016 Sep; 389(9):1009-20. IF: 2,558.
  22. Di Pietro N, Giardinelli A, Sirolli V, Riganti C, Di Tomo P, Gazzano E, Di Silvestre S, Panknin C, Cortese-Krott MM, Csonka C, Kelm M, Ferdinandy P, Bonomini M, Pandolfi A. Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients. Mol Cell Biochem. 2016 Jun; 417(1-2):155-67. IF: 2,669.
  23. Sódar BW, Kittel Á, Pálóczi K, Vukman KV, Osteikoetxea X, Szabó-Taylor K, Németh A, Sperlágh B, Baranyai T, Giricz Z, Wiener Z, Turiák L, Drahos L, Pállinger É, Vékey K, Ferdinandy P, Falus A, Buzás EI. Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection. Sci Rep. 2016 Apr 18; 6:24316. IF: 4,259.
  24. Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JP. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016 Jun 14; 37(23):1789-98. IF: 19,651.
  25. Rajtik T, Carnicka S, Szobi A, Giricz Z, O-Uchi J, Hassova V, Svec P, Ferdinandy P, Ravingerova T, Adameova A. Data on necrotic and apoptotic cell death in acute myocardial ischemia/reperfusion injury: the effects of CaMKII and angiotensin AT1 receptor inhibition. Data Brief. 2016 Mar 10; 7:730-4. IF: 0.
  26. Kiss K, Fekete V, Pálóczi J, Sárközy M, Murlasits Z, Pipis J, Kheyfets IA, Dugina JL, Sergeeva SA, Epstein OI, Csonka C, Csont T, Ferdinandy P, Bencsik P. Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats. Altern Ther Health Med. 2016 Mar-Apr; 22(2):10-7. IF: 1,247.
  27. Di Lisa F, Giorgio M, Ferdinandy P, Schulz R. New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases. Br J Pharmacol. 2016 Mar 15. IF: 5,491.
  28. Rajtik T, Carnicka S, Szobi A, Giricz Z, O-Uchi J, Hassova V, Svec P, Ferdinandy P, Ravingerova T, Adameova A. Oxidative activation of CaMKIIδ in acute myocardial ischemia/reperfusion injury: A role of angiotensin AT1 receptor-NOX2 signaling axis. Eur J Pharmacol. 2016 Jan 15; 771:114-22. IF: 2,896.
  29. Bencsik P, Kiss K, Gorbe A, Ferdinandy P. Response to letter entitled “Plasma MMPs in CAD patients” by Ceron CS et al. Eur J Clin Invest. 2016 Jan; 46(1):106-7. IF: 0.
  30. Kalász H, Tekes K, Pöstényi Z, Vizvári E, Sótonyi P, Szabó D, Tóth-Molnár E. Pharmacokinetics of Selegiline in a Rabbit Model. Lett Drug Des Discov. 2016, 13, 752-756. IF: 1,17.
  31. Kalász H. Evergreen Planar Chromatography. J. Chromatogr. Sci. 2016, Vol. 54, No. 7, 1075–1076. IF: 0.
  32. Ojha S, Syed M. Nurulain, S. Dhanasekaran, Mohammad Shafiullah, Abdu Adem, Charu Sharma, Kamil Kuca, Huba Kalasz. Blood-fetus penetration of pralidoxime. Mil. Med. Sci. Lett. 2016, vol. 85(2), p. 63-68. IF: 0.969.
  33. Dubois DJ, Jurczynska A, Kerpel-Fronius S, Kesselring G, Imamura K, Nell G, Silva H, Stonier P. Fostering Competence in Medicines Development: The IFAPP Perspective. Front. Pharmacol. 2016 Oct 14; 7:377. IF: 4,4.
  34. Benedek T, Maurovich-Horvat P, Ferdinandy P, Merkely B. The Use of Biomarkers for the Early Detection of Vulnerable Atherosclerotic Plaques and Vulnerable Patients. J. Cardiovascular Emergencies. 2016; 2(3):106-113. IF: 0.

2015

Number of publications: 41

Cumulative impact factor: 188,25

  1. Kiraly K, Caputi FF, Hanuska A, Kato E, Balogh M, Koles L, Palmisano M, Riba P, Hosztafi S, Romualdi P, Candeletti S, Ferdinandy P, Furst S, Al-Khrasani M. A new potent analgesic agent with reduced liability to produce morphine tolerance. Brain Res Bull. 2015 Aug; 117:32-8. 2,718
  2. Harsing LG Jr, Timar J, Szabo G, Udvari S, Nagy KM, Marko B, Zsilla G, Czompa A, Tapolcsanyi P, Kocsis A, Matyus P. Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms. Curr Pharm Des. 2015; 21(17):2291-303. IF: 3,452
  3. Gyires K, Toth VE, Zadori ZS. Gastric mucosal protection: from the periphery to the central nervous system. J Physiol Pharmacol. 2015 Jun; 66(3):319-29. IF: 2,386
  4. Ling I, Mihalik B, Etherington LA, Kapus G, Palvolgyi A, Gigler G, Kertesz S, Gaal A, Pallagi K, Kiricsi P, Szabo E, Szenasi G, Papp L, Harsing LG, Levay G, Spedding M, Lambert JJ, Belelli D, Barkoczy J, Volk B, Simig G, Gacsalyi I, Antoni FA. A novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential. Eur J Pharmacol. 2015 Oct 5; 764:497-507. IF: 2,532
  5. Hanuska A, Szenasi G, Albert M, Koles L, Varga A, Szabo A, Matyus P, Harsing LG Jr. Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions. Neurochem Res. 2015 Sep 12. [Epub ahead of print] IF: 2,593
  6. Delmaghani S, Defourny J, Aghaie A, Beurg M, Dulon D, Thelen N, Perfettini I, Zelles T, Aller M, Meyer A, Emptoz A, Giraudet F, Leibovici M, Dartevelle S, Soubigou G, Thiry M, Vizi ES, Safieddine S, Hardelin JP, Avan P, Petit C. Hypervulnerability to Sound Exposure through Impaired Adaptive Proliferation of Peroxisomes. Cell. 2015 Nov 5; 163 (4):894-906. IF: 32,242
  7. Szabo S, Gyires K. A szteroidok elnevezese, felosztasa es az emberi stresszfekelyek. Orvosi hetilap. 2015.
  8. Postenyi Z, Tekes K, Toth-Molnar E, Kalasz H. HPLC analysis of blood-brain barrier penetration of 4-fluorodeprenyl. J Pharm Biomed Anal. 2015 Jan; 102:529-34. IF: 2,979
  9. Adeghate E, Feher E, Kalasz H. Evaluating the Phase II drugs currently under investigation for diabetic neuropathy. Expert Opin Investig Drugs. 2015 Jan; 24 (1):1-15. Epub 2014 Aug 29. IF: 5,432
  10. Pickard JM, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, Ferdinandy P, Ganske R, Garcia-Dorado D, Giricz Z, Gourine AV, Heusch G, Kharbanda R, Kleinbongard P, MacAllister R, McIntyre C, Meybohm P, Prunier F, Redington A, Robertson NJ, Suleiman MS, Vanezis A, Walsh S, Yellon DM, Hausenloy DJ. Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol. 2015 Jan; 110 (1):453. IF: 5,414
  11. Baan JA, Varga ZV, Leszek P, Kuśmierczyk M, Baranyai T, Dux L, Ferdinandy P, Braun T, Mendler L. Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study. J Transl Med. 2015 Jan 16; 13:1. IF: 3,93
  12. Lecour S, Schulz R, Ferdinandy P, Hausenloy DJ. Platelet inhibitors influence cardioprotection: importance in preclinical study design: reply. Cardiovasc Res. 2015 Apr 1; 106(1):8. IF: 5,94
  13. Kirca M, Kleinbongard P, Soetkamp D, Heger J, Csonka C, Ferdinandy P, Schulz R. Interaction between connexin 43 and nitric oxide synthase in mice heart mitochondria. J Cell Mol Med. 2015 Apr; 19 (4):815-25. IF: 4,014
  14. Csont T, Murlasits Z, Menesi D, Kelemen JZ, Bencsik P, Pipicz M, Fekete V, Zvara A, Puskas LG, Ferdinandy P. Tissue-specific Gene Expression in Rat Hearts and Aortas in a Model of Vascular Nitrate Tolerance. J Cardiovasc Pharmacol. 2015 May; 65 (5):485-93. IF: 2,135
  15. Kalasz H, Nurulain SM, Veress G, Antus S, Darvas F, Adeghate E, Adem A, Hashemi F, Tekes K. Mini review on blood-brain barrier penetration of pyridinium aldoximes. J Appl Toxicol. 2015 Feb; 35 (2):116-23. IF: 2,982
  16. Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, Ferdinandy P. The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol. 2015 Mar; 172 (6):1587-606. IF: 4,842
  17. Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta. 2015 Feb; 1852 (2):232-42. IF: 4,882
  18. Pechanova O, Varga ZV, Cebova M, Giricz Z, Pacher P, Ferdinandy P. Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol. 2015 Mar; 172 (6):1415-33. IF: 4,842
  19. Schreckenberg R, Weber P, Cabrera-Fuentes HA, Steinert I, Preissner KT, Bencsik P, Sarkozy M, Csonka C, Ferdinandy P, Schulz R, Schluter KD. Mechanism and consequences of the shift in cardiac arginine metabolism following ischaemia and reperfusion in rats. Thromb Haemost. 2015 Mar; 113 (3):482-93. IF: 4,984
  20. Madonna R, Engel FB, Davidson SM, Ferdinandy P, Gorbe A, Sluijter JP, Van Laake LW. Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation. Curr Drug Targets. 2015; 16 (8):780-5. IF: 3,021
  21. Barlaka E, Gorbe A, Gaspar R, Paloczi J, Ferdinandy P, Lazou A. Activation of PPARβ/δ protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases. Pharmacol Res. 2015 May-Jun; 95-96:102-10. IF: 4,408
  22. Kalasz H. Forced-flow planar chromatography in the rear view mirror. J Chromatogr Sci. 2015 Mar; 53 (3):436-42. IF: 1,363
  23. Kalasz H. Introduction. Remembering Professor Csaba Horvath “Segui il tuo corso et lascia dir les genti (follow your own road, and let the people talk)”: -Dante Alighieri, the divine comedy. J Chromatogr Sci. 2015 Mar; 53 (3):393. IF: 1,363
  24. Kerpel-Fronius S, Rosenkranz B, Allen E, Bass R, Mainard JD, Dodoo A, Dubois DJ, Hela M, Kern S, Massud J, Silva H, Whitty J. Education and training for medicines development, regulation, and clinical research in emerging countries. Front Pharmacol. 2015 Apr 14; 6:80. IF: 3,802
  25. Stanulović V, Kadlecova P, Zelko R, Kerpel-Fronius S. Earlier identification of risks: cumulative probability analysis of time to safety alerts for therapeutic monoclonal antibodies. Int J Clin Pharmacol Ther. 2015 Jul;53(7):499-503. IF: 1,223
  26. Schreckenberg R, Rebelo M, Deten A, Weber M, Rohrbach S, Pipicz M, Csonka C, Ferdinandy P, Schulz R, Schluter KD. Specific Mechanisms Underlying Right Heart Failure: The Missing Upregulation of Superoxide Dismutase-2 and Its Decisive Role in Antioxidative Defense. Antioxid Redox Signal. 2015 Nov 20;23(15):1220-32. IF: 7,407
  27. Madonna R, Cadeddu C, Deidda M, Giricz Z, Madeddu C, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Varga ZV, Zito C, Geng YJ, Mercuro G, Ferdinandy P. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol. 2015 Jul 15; 191:203-10. IF: 4,036
  28. Bencsik P, Sasi V, Kiss K, Kupai K, Kolossvary M, Maurovich-Horvat P, Csont T, Ungi I, Merkely B, Ferdinandy P. Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients. Eur J Clin Invest. 2015 Jul; 45 (7):692-701. IF: 2,734
  29. Varga ZV, Giricz Z, Bencsik P, Madonna R, Gyongyosi M, Schulz R, Mayr M, Thum T, Puskas LG, Ferdinandy P. Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification. Curr Drug Targets. 2015;16(8):904-11. IF: 3,021
  30. Papapetropoulos A, Foresti R, Ferdinandy P. Pharmacology of the ‘gasotransmitters’ NO, CO and H2S: translational opportunities. Br J Pharmacol. 2015 Mar;172(6):1395-6. IF: 4,842
  31. Madonna R, Petrov L, Teberino MA, Manzoli L, Karam JP, Renna FV, Ferdinandy P, Montero-Menei CN, Ylä-Herttuala S, De Caterina R. Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. Cardiovasc Res. 2015 Oct 1; 108 (1):39-49. IF: 5,94
  32. Gorbe A, Eder A, Varga ZV, Paloczi J, Hansen A, Ferdinandy P, Eschenhagen T. Protection by the NO-Donor SNAP and BNP against Hypoxia/Reoxygenation in Rat Engineered Heart Tissue. PLoS One. 2015 Jul 6; 10 (7):e0132186. IF: 3,234
  33. Sarkozy M, Szucs G, Pipicz M, Zvara A, Eder K, Fekete V, Szucs C, Barkanyi J, Csonka C, Puskas LG, Konya C, Ferdinandy P, Csont T. The effect of a preparation of minerals, vitamins and trace elements on the cardiac gene expression pattern in male diabetic rats. Cardiovasc Diabetol. 2015 Jun 28; 14:85. IF: 4,015
  34. Schulz R, Gorge PM, Gorbe A, Ferdinandy P, Lampe PD, Leybaert L. Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. Pharmacol Ther. 2015 Sep; 153:90-106. IF: 9,723
  35. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Nov; 309(9):H1453-67. IF: 3,838
  36. Tekes K, Postenyi Z, Faigl EB, Magyar K, Polyak A, Trencsenyi G, Balogh L, Kalasz H. Distribution of N-methyl-(14) C-labeled selegiline in the rat. J Pharm Biomed Anal. 2015 Jul 10; 111:147-52. IF: 2,979
  37. Nurulain SM, Ojha S, Tekes K, Shafiullah M, Kalasz H, Adem A. Efficacy of N-Acetylcysteine, Glutathione, and Ascorbic Acid in Acute Toxicity of Paraoxon to Wistar Rats: Survival Study. Oxid Med Cell Longev. 2015; 2015:329306. IF: 3,516
  38. Baranyai T, Nagy CT, Koncsos G, Onodi Z, Karolyi-Szabo M, Makkos A, Varga ZV, Ferdinandy P, Giricz Z. Acute hyperglycemia abolishes cardioprotection by remote ischemic perconditioning. Cardiovasc Diabetol. 2015 Nov 18; 14:151. IF: 4,015
  39. Bencsik P, Kiss K, Gorbe A, Ferdinandy P. Response to letter entitled Plasma MMPs in CAD patients by Ceron CS et al. Eur J Clin Invest. 2016 Jan; 46 (1):106-7. IF: 2,734
  40. Baranyai T, Herczeg K, Onodi Z, Voszka I, Modos K, Marton N, Nagy G, Mäger I, Wood MJ, El Andaloussi S, Palinkas Z, Kumar V, Nagy P, Kittel A, Buzas E, Ferdinandy P, Giricz Z. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS One. 2015 Dec 21; 10 (12): e0145686. IF: 3,234
  41. Rajtik T, Carnicka S, Szobi A, Giricz Z, O-Uchi J, Hassova V, Svec P, Ferdinandy P, Ravingerova T, Adameova A. Oxidative activation of CaMKIIδ in acute myocardial ischemia/reperfusion injury: A role of angiotensin AT1 receptor-NOX2 signaling axis. Eur J Pharmacol. 2015 Dec 13; 771:114-122. IF: 2,532

2014

Number of publications: 38

Cumulative impact factor: 147,5

  1. Varga J, Klausz B, Domokos A, Kalman S, Pakaski M, Szucs S, Garab D, Zvara A, Puskas L, Kalman J, Timar J, Bagdy G, Zelena D. Increase in Alzheimer’s related markers preceeds memory disturbances: studies in vasopressin-deficient Brattleboro rat. Brain Res Bull. 2014 Jan; 100:6-13. IF: 2,718
  2. Horvath G, Goloncser F, Csolle C, Kiraly K, Ando RD, Baranyi M, Kovanyi B, Mate Z, Hoffmann K, Algaier I, Baqi Y, Muller CE, Von Kugelgen I, Sperlagh B. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis. 2014 Oct; 70:162-78 IF: 5,078
  3. Shaqura M, Khalefa BI, Shakibaei M, Zollner C, Al-Khrasani M, Furst S, Schäfer M, Mousa SA. New insights into mechanisms of opioid inhibitory effects on capsaicin-induced TRPV1 activity during painful diabetic neuropathy. Neuropharmacology. 2014 Oct; 85:142-50. IF: 5,106
  4. Miklya I. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacol Rep. 2014 Jun; 66(3):453-8. IF: 1,928
  5. Miklya I, Pencz N, Hafenscher F, Goltl P. Az alpha-szinuklein szerepe Parkinson-korban. Neuropsychopharmacologia Hungarica. 2014.
  6. Miklya I, Goltl P, Hafenscher F, Pencz N. A parkin szerepe a Parkinson-korban. Neuropsychopharmacologia Hungarica. 2014.
  7. Gyires K, Ronai AZ, Zadori ZS, Toth VE, Nemeth J, Szekeres M, Hunyady L. Angiotensin II-induced activation of central AT1 receptors exerts endocannabinoid-mediated gastroprotective effect in rats. Mol Cell Endocrinol. 2014 Feb 15; 382(2):971-8. IF: 4,405
  8. Polony G, Humli V, Ando R, Aller M, Horvath T, Harnos A, Tamas L, Vizi ES, Zelles T. Protective effect of rasagiline in aminoglycoside ototoxicity. Neuroscience. 2014 Apr 18; 265:263-73. IF: 3,357
  9. Koncz I, Szasz BK, Szabo SI, Kiss JP, Mike A, Lendvai B, Sylvester Vizi E, Zelles T. The tricyclic antidepressant desipramine inhibited the neurotoxic, kainate-induced [Ca(2+)]i increases in CA1 pyramidal cells in acute hippocampal slices. Brain Res Bull. 2014 May; 104:42-51. IF: 2,718
  10. Zadori ZS, Toth VE, Feher A, Philipp K, Nemeth J, Gyires K. Evidence for the gastric cytoprotective effect of centrally injected agmatine. Brain Res Bull. 2014 Sep; 108:51-9. IF: 2,718
  11. Gyires K, Zadori ZS. Brain neuropeptides in gastric mucosal protection. Curr Opin Pharmacol. 2014 Dec; 19:24-30. IF: 4,595
  12. Gyires K, Toth EV, Zadori SZ. Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Curr Pharm Des. 2014;20(7):1063-81. IF: 3,452
  13. Ficker C, Rozmer K, Kato E, Ando RD, Schumann L, Krugel U, Franke H, Sperlagh B, Riedel T, Illes P. Astrocyte-neuron interaction in the substantia gelatinosa of the spinal cord dorsal horn via P2X7 receptor-mediated release of glutamate and reactive oxygen species. Glia. 2014 Oct; 62(10):1671-86. IF: 6,031
  14. Gyires K. Central neuroendocrine mechanisms of gastroprotection. Ideggyogyaszati szemle. 2014.
  15. Giricz Z, Varga ZV, Baranyai T, Sipos P, Paloczi K, Kittel A, Buzas EI, Ferdinandy P. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. J Mol Cell Cardiol. 2014 Mar; 68:75-8. IF: 4,655
  16. Csonka C, Szucs G, Varga-Orvos Z, Bencsik P, Csont T, Zvara A, Puskas LG, Ferdinandy P. Ischemic postconditioning alters the gene expression pattern of the ischemic heart. Exp Biol Med (Maywood). 2014 Feb; 239(2):141-50. IF: 2,165
  17. Bencsik P, Paloczi J, Kocsis GF, Pipis J, Belecz I, Varga ZV, Csonka C, Gorbe A, Csont T, Ferdinandy P. Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacol Res. 2014 Feb; 80:36-42. IF: 4,408
  18. Kadomatsu K, Bencsik P, Gorbe A, Csonka C, Sakamoto K, Kishida S, Ferdinandy P. Therapeutic potential of midkine in cardiovascular disease. Br J Pharmacol. 2014 Feb; 171(4):936-44. IF: 4,842
  19. Hashemi F, Laufer R, Szegi P, Csomor V, Kalasz H, Tekes K. HPLC determination of brain biogenic amines following treatment with bispyridinium aldoxime K203. Acta Physiol Hung. 2014 Mar; 101(1):40-6. IF: 0,734
  20. Csonka C, Kupai K, Bencsik P, Gorbe A, Paloczi J, Zvara A, Puskas LG, Csont T, Ferdinandy P. Cholesterol-enriched diet inhibits cardioprotection by ATP-sensitive K+ channel activators cromakalim and diazoxide. Am J Physiol Heart Circ Physiol. 2014 Feb; 306(3):H405-13. IF: 3,838
  21. Rassaf T, Ferdinandy P, Schulz R. Nitrite in organ protection. Br J Pharmacol. 2014 Jan; 171(1):1-11. IF: 4,842
  22. Petroianu G, Gagani Athauda, Ferenc Darvas, Huba Kalasz, Dietrich E Lorke. K-Oxime (K-27): Phosphylation-induced changes in log-P. Mil Med Sci Let. 2014. IF: 0,771
  23. Varga ZV, Zvara A, Farago N, Kocsis GF, Pipicz M, Gaspar R, Bencsik P, Gorbe A, Csonka C, Puskas LG, Thum T, Csont T, Ferdinandy P. MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs. Am J Physiol Heart Circ Physiol. 2014 Jul 15; 307 (2): H216-27. IF: 3,838
  24. Madonna R, Geng YJ, Bolli R, Rokosh G, Ferdinandy P, Patterson C, De Caterina R. Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. J Biol Chem. 2014 Jul 11; 289 (28):19585-98. IF: 4,573
  25. Sluijter JP, Condorelli G, Davidson SM, Engel FB, Ferdinandy P, Hausenloy DJ, Lecour S, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Van Laake LW; Nucleus of the European Society of Cardiology Working Group Cellular Biology of the Heart. Novel therapeutic strategies for cardioprotection. Pharmacol Ther. 2014 Oct; 144 (1):60-70. IF: 9,723
  26. Kalasz H, Magyar K, Szoke E, Adeghate E, Adem A, Hasan MY, Nurulain SM, Tekes K. Metabolism of selegiline [(-)-deprenyl)]. Curr Med Chem. 2014;21(13):1522-30. IF: 3,853
  27. Gorbe A, Varga ZV, Paloczi J, Rungarunlert S, Klincumhom N, Pirity MK, Madonna R, Eschenhagen T, Dinnyes A, Csont T, Ferdinandy P. Cytoprotection by the NO-donor SNAP against ischemia/reoxygenation injury in mouse embryonic stem cell-derived cardiomyocytes. Mol Biotechnol. 2014 Mar; 56 (3):258-64. IF: 1,876
  28. Csonka C, Pali T, Bencsik P, Gorbe A, Ferdinandy P, Csont T. Measurement of NO in biological samples. Br J Pharmacol. 2015 Mar; 172 (6):1620-32. IF: 4,842
  29. Madonna R, Geng YJ, Shelat H, Ferdinandy P, De Caterina R. High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. Biochim Biophys Acta. 2014 Nov; 1842 (11):2266-75. IF: 4,882
  30. Sarkozy M, Fekete V, Szucs G, Torok S, Szucs C, Barkanyi J, Varga ZV, Foldesi I, Csonka C, Konya C, Csont T, Ferdinandy P. Anti-diabetic effect of a preparation of vitamins, minerals and trace elements in diabetic rats: a gender difference. BMC Endocr Disord. 2014 Aug 26; 14:72. IF: 1,71
  31. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014 Oct; 66 (4):1142-74. IF: 17,099
  32. Pavo N, Emmert MY, Giricz Z, Varga ZV, Ankersmit HJ, Maurer G, Hoerstrup SP, Ferdinandy P, Wu JC, Gyongyosi M. On-line visualization of ischemic burden during repetitive ischemia/reperfusion. JACC Cardiovasc Imaging. 2014 Sep; 7 (9):956-8. IF: 7,188
  33. Csomor, Laufer R, Postenyi Z, Kalasz H, Adeghate E, Nurulain SM, Tekes K, Adem A. HPLC Analysis and Detection of L –Deprenyl. Acta Cromatographica. 2014. IF: 0,577
  34. Madonna R, Ferdinandy P, De Caterina R, Willerson JT, Marian AJ. Recent developments in cardiovascular stem cells. Circ Res. 2014 Dec 5; 115 (12):e71-8. IF: 11,019
  35. Lecour S, Botker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014 Dec 1; 104 (3):399-411. IF: 5,94
  36. Katengua-Thamahane E, Marnewick JL, Ajuwon OR, Chegou NN, Szucs G, Ferdinandy P, Csont T, Csonka C, Van Rooyen J. The combination of red palm oil and rooibos show anti-inflammatory effects in rats. J Inflamm (Lond). 2014 Dec 20; 11 (1):41. IF: 2,024
  37. Lotfy M, Kalasz H, Szalai G, Singh J, Adeghate E. Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus. Open Med Chem J. 2014 Dec 31; 8:28-35
  38. Kerpel-Fronius S. International training of specialists inmedicine development in Hungarian. Nemzetkozi gyogyszerfejleszto szakemberekkepzese a Semmelweis Egyetemen IME, 13:51-55 2014.

2013

Number of publications: 45

Cumulative impact factor: 118,01

  1. Szentirmay AK, Kiraly KP, Lenkey N, Lacko E, Al-Khrasani M, Friedmann T, Timar J, Gyarmati S, Toth G, Furst S, Riba P. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice. Brain Res Bull. 2013 Jan; 90:66-71 IF: 2,974
  2. Shaqura M1, Khalefa BI, Shakibaei M, Winkler J, Al-Khrasani M, Furst S, Mousa SA, Schäfer M. Reduced number, G protein coupling, and antinociceptive efficacy of spinal mu-opioid receptors in diabetic rats are reversed by nerve growth factor. J Pain. 2013 Jul;14(7):720-30 IF: 4,216
  3. Schmidhammer H, Spetea M, Windisch P, Schutz J, Riba P, Al-Khrasani M, Furst S. Functionalization of the carbonyl group in position 6 of morphinan-6-ones. Development of novel 6-amino and 6-guanidino substituted 14-alkoxymorphinans. Curr Pharm Des. 2013; 19(42):7391-9. IF: 3,288
  4. Khalefa BI, Mousa SA, Shaqura M, Lacko E, Hosztafi S, Riba P, Schäfer M, Ferdinandy P, Furst S, Al-Khrasani M. Peripheral antinociceptive efficacy and potency of a novel opioid compound 14-O-MeM6SU in comparison to known peptide and non-peptide opioid agonists in a rat model of inflammatory pain. Eur J Pharmacol. 2013 Aug 5; 713 (1-3):54-7. IF: 2,684
  5. Komlos G, Kormoczi K, Miklya I, Joob-Fancsaly A. [Guidelines on the pharmacotherapy of the dental patient during pregnancy].[Article in Hungarian] Fogorv Sz. 2013 Mar; 106 (1):39-44.
  6. Sobor, Timar J, Riba P, Kiraly K P, Al-Khrasani M, Gyarmati Zs, Furst Zs. Viselkedesi vizsgalatok a gesztacios-laktacios idoszakban morfin-kezelt patkanyon. Neuropsychopharmacologia Hungarica. 2013.
  7. Furst Z, Riba P, Al-Khrasani M. New approach to the neurobiological mechanisms of addiction. Neuropsychopharmacol Hung. 2013 Dec; 15 (4):189-205.
  8. Gacsalyi I, Nagy K, Pallagi K, Levay G, Harsing LG Jr, Moricz K, Kertesz S, Varga P, Haller J, Gigler G, Szenasi G, Barkoczy J, Biro J, Spedding M, Antoni F. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents. Neuropharmacology. 2013 Jan; 64:254-63 IF: 4,819
  9. Harsing LG Jr. An overview on GLYT-1 inhibitors under evaluation for the treatment of schizophrenia, Drugs of the Future. 2013. IF: 0,253
  10. Harsing LG Jr, Matyus P. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters. Brain Res Bull. 2013 Apr; 93:110-9. IF: 2,974
  11. Kertesz S, Szabo G, Udvari S, Levay G, Matyus P, Harsing LG Jr. Temporal alteration of spreading depression by the glycine transporter type-1 inhibitors NFPS and Org-24461 in chicken retina. Brain Res. 2013 Jan 25; 1492:1-6. IF: 2,828
  12. Brancati SB, Zadori ZS, Nemeth J, Gyires K. Substance P induces gastric mucosal protection at supraspinal level via increasing the level of endomorphin-2 in rats. Brain Res Bull. 2013 Feb; 91:38-45. IF: 2,974
  13. Zadori ZS, Gyires K. In vivo measurement of intragastric pressure with a rubber balloon in the anesthetized rat. Curr Protoc Toxicol. 2013 Sep 23; 57:Unit 21.12.
  14. Zadori ZS, Feher A, Al-Khrasani M, Lacko E, Toth VE, Brancati SB, Hein L, Matyus P, Gyires K. Imidazoline versus alpha₂-adrenoceptors in the control of gastric motility in mice. Eur J Pharmacol. 2013 Apr 5; 705(1-3):61-7. IF: 2,684
  15. Kiss B, Gyires K, Kellermayer M, Laszlo JF. Lateral gradients significantly enhance static magnetic field-induced inhibition of pain responses in mice–a double blind experimental study. Bioelectromagnetics. 2013 Jul; 34(5):385-96. IF: 1,859
  16. Tabi T, Szoko E, Merey A, Toth V, Matyus P, Gyires K. Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation. J Neural Transm (Vienna). 2013 Jun; 120(6):963-7. IF: 2,871
  17. Gyires K, Nemeth J, Zadori ZS. Gastric mucosal protection and central nervous system. Curr Pharm Des. 2013;19(1):34-9. IF: 3,288
  18. Koles L, Garção P, Zadori ZS, Ferreira SG, Pinheiro BS, da Silva-Santos CS, Ledent C, Kofalvi A. Presynaptic TRPV1 vanilloid receptor function is age- but not CB1 cannabinoid receptor-dependent in the rodent forebrain. Brain Res Bull. 2013 Aug; 97:126-35. IF: 2,974
  19. Vizi ES, Kisfali M, Lorincz T. Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. Brain Res Bull. 2013 Apr; 93:32-8. IF: 2,974
  20. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013 Jun; 19(6):355-67. IF: 10,11
  21. Csolle C, Baranyi M, Zsilla G, Kittel A, Goloncser F, Illes P, Papp E, Vizi ES, Sperlagh B. Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors. PLoS One. 2013 Jun 21; 8(6):e66547. Print 2013. IF: 3,534
  22. Balazs B, Danko T, Kovacs G, Koles L, Hediger MA, Zsembery A. Investigation of the inhibitory effects of the benzodiazepine derivative, 5-BDBD on P2X4 purinergic receptors by two complementary methods. Cell Physiol Biochem. 2013; 32(1):11-24. IF: 3,55
  23. Krugel U, Koles L, Illes P. Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms. Neuropsychopharmacol Hung. 2013 Dec; 15 (4):206-13.
  24. Kisfali M, Lrincz T, Vizi ES. Comparison of Ca2+ transients and [Ca2+]i in the dendrites and boutons of non-fast-spiking GABAergic hippocampal interneurons using two-photon laser microscopy and high- and low-affinity dyes. J Physiol. 2013 Nov 15; 591 (Pt 22):5541-53. IF: 4,544
  25. Nurulain SM, Petroianu G, Shafiullah M, Kalasz H, Oz M, Saeed T, Adem A, Adeghate E. Sub-chronic exposure to paraoxon neither induces nor exacerbates diabetes mellitus in Wistar rat. J Appl Toxicol. 2013 Oct; 33 (10):1036-43. IF: 3,174
  26. Tekes K, Szegi P, Hashemi F, Laufer R, Kalasz H, Siddiq A, Ertsey C. Medicinal chemistry of antimigraine drugs. Curr Med Chem. 2013; 20 (26):3300-16. IF: 3,715
  27. Kalasz H, Szegi P, Janoki G, Balogh L, Postenyi Z, Musilek K, Petroianu GA, Siddiq A, Tekes K. Study on medicinal chemistry of K203 in wistar rats and beagle dogs. Curr Med Chem. 2013;20(16):2137-44. IF: 3,715
  28. Kalasz H, Nurulain SM, Szegi P, Kuca K, Adem A, Hasan MYB, Hashemi F, Tekes K. HPLC Analysis in Drug Level Monitoring of K027. Acta Chromatographica. 2013. IF: 0,485
  29. Kalasz H, Petroianu G, Hosztafi S, Darvas F, Csermely T, Adeghate E, Siddiq A, Tekes K. Medicinal chemistry of drugs with active metabolites following conjugation. Mini Rev Med Chem. 2013 Oct; 13 (11):1550-63. IF: 3,186
  30. Tekes K, Tariq S, Adeghate E, Laufer R, Hashemi F, Siddiq A, Kalasz H. Nociceptinergic system as potential target in Parkinson’s disease. Mini Rev Med Chem. 2013 Aug;13(10):1389-97. IF: 3,186
  31. Oommen D, Giricz Z, Srinivas UK, Samali A. Atypical heat shock response and acquisition of thermotolerance in P388D1 cells. Biochem Biophys Res Commun. 2013 Jan 4; 430 (1):236-40. IF: 2,281
  32. Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis GF, Pipis J, Szucs G, Csonka C, Puskas LG, Ferdinandy P, Csont T. Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats. Cardiovasc Diabetol. 2013 Jan 15; 12:16. IF: 3,706
  33. Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013 Apr 1; 98 (1):7-27. IF: 5,808
  34. Hill C, Wurfel A, Heger J, Meyering B, Schluter KD, Weber M, Ferdinandy P, Aronheim A, Schulz R, Euler G. Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovasc Res. 2013 Jul 1; 99 (1):121-8. IF: 5,808
  35. Madonna R, Gorbe A, Ferdinandy P, De Caterina R. Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells. Mol Biotechnol. 2013 Oct; 55 (2):169-78. IF: 2,275
  36. Fekete V, Murlasits Z, Aypar E, Bencsik P, Sarkozy M, Szenasi G, Ferdinandy P, Csont T. Myocardial postconditioning is lost in vascular nitrate tolerance. J Cardiovasc Pharmacol. 2013 Sep; 62 (3):298-303. IF: 2,111
  37. Szucs G, Murlasits Z, Torok S, Kocsis GF, Paloczi J, Gorbe A, Csont T, Csonka C, Ferdinandy P. Cardioprotection by farnesol: role of the mevalonate pathway. Cardiovasc Drugs Ther. 2013 Aug; 27 (4):269-77. IF: 2,952
  38. Varga ZV, Kupai K, Szucs G, Gaspar R, Paloczi J, Farago N, Zvara A, Puskas LG, Razga Z, Tiszlavicz L, Bencsik P, Gorbe A, Csonka C, Ferdinandy P, Csont T. MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol. 2013 Sep; 62:111-21. IF: 5,218
  39. Kistamas K, Szentandrassy N, Hegyi B, Ruzsnavszky F, Vaczi K, Barandi L, Horvath B, Szebeni A, Magyar J, Banyasz T, Kecskemeti V, Nanasi PP. Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes. Eur J Pharmacol. 2013 Jun 15; 710 (1-3):10-9. IF: 2,684
  40. Boeynaems JM, Canivet C, Chan A, Clarke MJ, Cornu C, Daemen E, Demotes J, Nys KD, Hirst B, Hundt F, Kassai B, Kerpel-Fronius S, Kiessig L, Klech H, Kraehenbuhl JP, Lafolie P, Lucht M, Niese D, Pauli-Magnus C, Peters B, Schaltenbrand R, Stockis A, Stykova M, Verheus N, Klingmann I. A European approach to clinical investigator training. Front Pharmacol. 2013 Sep 9; 4:112.
  41. Silva H, Stonier P, Buhler F, Deslypere JP, Criscuolo D, Nell G, Massud J, Geary S, Schenk J, Kerpel-Fronius S, Koski G, Clemens N, Klingmann I, Kesselring G, van Olden R, Dubois D. Core competencies for pharmaceutical physicians and drug development scientists. Front Pharmacol. 2013 Aug 26; 4:105.
  42. Kerpel-Fronius S. The Development of Pharmaceutical Medicine in Hungary. Pharmaceutical Medicine. 2013.
  43. Kerpel-Fronius S. A biohasonlo gyogyszerek klinikai alkalmazasa. Magyar Belorvosi Archivum. 2013.
  44. Csont T, Sarkozy M, Szucs G, Szucs C, Barkanyi J, Bencsik P, Gaspar R, Foldesi I, Csonka C, Konya C, Ferdinandy P. Effect of a multivitamin preparation supplemented with phytosterol on serum lipids and infarct size in rats fed with normal and high cholesterol diet. Lipids Health Dis. 2013 Sep 25; 12:138. IF: 2,31
  45. Petroianu, Lorke E, Athauda G, Darvas F, Kalasz H. Pralidoxime and Obidoxime: Phosphylation-induced Changes in logP (partition coefficient). Journal of Environment al Immunology and Toxicology. 2013.

2012

Number of publications: 20

Cumulative impact factor: 48,98

  1. Al-Khrasani M, Lacko E, Riba P, Kiraly K, Sobor M, Timar J, Mousa S, Schäfer M, Furst S. The central versus peripheral antinociceptive effects of μ-opioid receptor agonists in the new model of rat visceral pain. Brain Res Bull. 2012 Feb 10; 87(2-3):238-43. IF: 2,935
  2. Khalefa BI, Shaqura M, Al-Khrasani M, Furst S, Mousa SA, Schäfer M. Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids. Eur J Pain. 2012 May; 16(5):690-705. IF: 3,062
  3. Alberti A, Beni S, Lacko E, Riba P, Al-Khrasani M, Kery A. Characterization of phenolic compounds and antinociceptive activity of Sempervivum tectorum L. leaf juice. J Pharm Biomed Anal. 2012 Nov; 70:143-50. IF: 2,947
  4. Lacko E, Varadi A, Rapavi R, Zador F, Riba P, Benyhe S, Borsodi A, Hosztafi S, Timar J, Noszal B, Furst S, Al-Khrasani M. A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy. Curr Med Chem. 2012;19(27):4699-707. IF: 4,07
  5. Ständker L, Harvey AL, Furst S, Mathes I, Forssmann WG, Escalona de Motta G, Beress L. Improved method for the isolation, characterization and examination of neuromuscular and toxic properties of selected polypeptide fractions from the crude venom of the Taiwan cobra Naja naja atra. Toxicon. 2012 Sep 15;60(4):623-31. IF: 2,924
  6. Kovacs A, Harsing LG Jr, Szenasi G. Vasoconstrictor 5-HT receptors in the smooth muscle of the rat middle cerebral artery. Eur J Pharmacol. 2012 Aug 15;689(1-3):160-4. IF: 2,592
  7. Harsing LG, Zsilla G, Matyus P, Nagy KM, Marko B, Gyarmati Z, Timar J. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules – glycine transporter type 1 and its inhibitors (review). Acta Physiol Hung. 2012 Mar;99(1):1-17. IF: 0,882
  8. Harsing LG Jr, Albert M, Matyus P, Szenasi G. Inhibition of hypoxia-induced [(3)H]glycine release from chicken retina by the glycine transporter type-1 (GlyT-1) inhibitors NFPS and Org-24461. Exp Eye Res. 2012 Jan;94(1):6-12. IF: 3,026
  9. Stankovics L, Gyires K. Farmakovigilancia 2012. Gyogyszereink. 2012
  10. Enzsoly. P. Dunkel A. Czompa R. Ceme K. Gyires K. Magyar J. Nemeth P. Matyus. Szemikarbazid-szenzitiv amin oxidaz gatlok mint uj hatoanyagok gyulladasos szembetegsegek kezelesere: Szelektiv inhibitoroktol uj tipusu tobb-tamadaspontu gyulladasgatlo gyogyszerjeloltig. Magyar Tudomany. 2012.
  11. Hartyanszky I, Kalasz H, Adeghate E, Gulyas Z, Hasan MY, Tekes K, Adem A, Sotonyi P. Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs. Curr Drug Metab. 2012 Jul;13(6):835-62. IF: 4,405
  12. Petroianu, Lorke D., Kalasz H. Comparison of the ability of pyridinium aldoximes to reactivate human red blood cell acetylcolinestrases inhibited by ethyl- and methyl-paraoxon. Curr Org Chem. 2012. IF: 3,039
  13. Ram N, Kalasz H, Adeghate E, Darvas F, Hashemi F, Tekes K. Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations). Curr Med Chem. 2012;19(33):5683-704. IF: 4,07
  14. Kocsis GF, Sarkozy M, Bencsik P, Pipicz M, Varga ZV, Paloczi J, Csonka C, Ferdinandy P, Csont T. Preconditioning protects the heart in a prolonged uremic condition. Am J Physiol Heart Circ Physiol. 2012 Nov 15;303(10):H1229-36. 2012. IF: 3,71
  15. Gupta S, Giricz Z, Natoni A, Donnelly N, Deegan S, Szegezdi E, Samali A. NOXA contributes to the sensitivity of PERK-deficient cells to ER stress. FEBS Lett. 2012 Nov 16;586(22):4023-30. IF: 3,582
  16. Monostori P, Kocsis GF, Okros Z, Bencsik P, Czetenyi O, Kiss Z, Gellen B, Bereczki C, Ocsovszki I, Pipis J, Paloczi J, Sarkozy M, Torok S, Varga IS, Kiss I, Fodor E, Csont T, Ferdinandy P, Turi S. Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. Clin Exp Nephrol. 2013 Aug;17(4):569-74. IF: 1,246
  17. Richter H, Teixeira FM, Ferreira SG, Kittel A, Kofalvi A, Sperlagh B. Presynaptic α₂-adrenoceptors control the inhibitory action of presynaptic CB₁ cannabinoid receptors on prefrontocortical norepinephrine release in the rat. Neuropharmacology. 2012 Oct;63(5):784-97. IF: 4,114
  18. Kerpel-Fronius S, Renczes G, Gyogyszervizsgalatok a gyermekkorban. Focus Medicinae. 2013.
  19. Giricz Z, Mentzer RM Jr, Gottlieb RA. Autophagy, myocardial protection, and the metabolic syndrome. J Cardiovasc Pharmacol. 2012 Aug;60(2):125-32. IF: 2,383
  20. Csomor V, Hashemi F, Laufer R, Szegi P, Hantos M, Kalasz H, Tekes K. Gyogyszerek okozta izerzekelesi zavarok. Gyogyszereszet. 2012.

2011

Number of publications: 15

Cumulative impact factor: 47,6

  1. Sobor M, Timar J, Riba P, Friedmann T, Kiraly KP, Gyarmati S, Al-Khrasani M, Furst S. Effects of opioid agonist and antagonist in dams exposed to morphine during the perinatal period. Brain Res Bull. 2011 Jan 15;84(1):53-60. IF: 2,818
  2. Spetea M, Windisch P, Guo Y, Bileviciute-Ljungar I, Schutz J, Asim MF, Berzetei-Gurske IP, Riba P, Kiraly K, Furst S, Al-Khrasani M, Schmidhammer H. Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies. J Med Chem. 2011 Feb 24;54(4):980-8. IF: 5,248
  3. Klausz B, Pinter O, Sobor M, Gyarmati Z, Furst Z, Timar J, Zelena D. Changes in adaptability following perinatal morphine exposure in juvenile and adult rats. Eur J Pharmacol. 2011 Mar 5;654(2):166-72. IF: 2,516
  4. Kiraly K, Lambeir AM, Szalai J, Szentirmay A, Luyten W, Barna I, Puskar Z, Kozsurek M, Ronai AZ. The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord. Eur J Pharmacol. 2011 Jan 10;650(1):195-9. IF: 2,516
  5. Riba P, Fajdalomcsillapitas a gyermekgyogyaszatban. Gyogyszereszet. 2011.
  6. Virok DP, Kis Z, Szegedi V, Juhasz G, Zvara A Jr, Muller G, Levay G, Harsing LG, Rajko R, Penke B, Janka Z, Janaky T, Puskas LG. Functional changes in transcriptomes of the prefrontal cortex and hippocampus in a mouse model of anxiety. Pharmacol Rep. 2011;63(2):348-61. IF: 2,445
  7. Shujaa N, Al-Khrasani M, Zadori ZS, Rossi M, Matyus P, Nemeth J, Hein L, Gyires K. α(2)-adrenoceptor agonist-induced inhibition of gastric motor activity is mediated by α(2A)-adrenoceptor subtype in the mouse. Neurochem Int. 2011 May;58(6):708-13. IF: 2,857
  8. Zadori ZS, Shujaa N, Brancati SB, Hein L, Gyires K. Both α2B- and α2C-adrenoceptor subtypes are involved in the mediation of centrally induced gastroprotection in mice. Eur J Pharmacol. 2011 Nov 1;669(1-3):115-20. IF: 2,516
  9. Dunkel P, Balogh B, Meleddu R, Maccioni E, Gyires K, Matyus P. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat. 2011 Sep;21(9):1453-71. IF: 3,571
  10. Laszlo JF, Szilvasi J, Fenyi A, Szalai A, Gyires K, Porszasz R. Daily exposure to inhomogeneous static magnetic field significantly reduces blood glucose level in diabetic mice. Int J Radiat Biol. 2011 Jan;87(1):36-45. IF: 2,275
  11. Bodnar M, Wang H, Riedel T, Hintze S, Kato E, Fallah G, Groger-Arndt H, Giniatullin R, Grohmann M, Hausmann R, Schmalzing G, Illes P, Rubini P. Amino acid residues constituting the agonist binding site of the human P2X3 receptor. J Biol Chem. 2011 Jan 28;286(4):2739-49. IF: 4,773
  12. Tekes K, Kalasz H, Hasan MY, Adeghate E, Darvas F, Ram N, Adem A. Aliphatic and aromatic oxidations, epoxidation and S-oxidation of prodrugs that yield active drug metabolites. Curr Med Chem. 2011;18(32):4885-900. IF: 4,859
  13. Kursinszki, Kalasz H., Szoke E., Adeghate E., Hassan MY. and Adem A. Comparative analysis of six different brands of date fruits. Acta Chromatogr. 2011, IF: 0,76
  14. Tekes K, Hashemi F, Szegi P, Sotonyi P, Laufer R, Kalasz H. Prodrugs and active metabolites among antidepressive compounds. Neuropsychopharmacol Hung. 2011 Jun;13(2):103-10.
  15. Adeghate E, Adem A, Hasan MY, Tekes K, Kalasz H. Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. Open Med Chem J. 2011;5(Suppl 2):93-8.
  16. Lotfy M, Singh J, Kalasz H, Tekes K, Adeghate E. Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J. 2011;5(Suppl 2):82-92.
  17. Adeghate E, Kalasz H. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J. 2011;5(Suppl 2):78-81.
  18. Singh J, Cumming E, Manoharan G, Kalasz H, Adeghate E. Medicinal chemistry of the anti-diabetic effects of momordica charantia: active constituents and modes of actions. Open Med Chem J. 2011;5(Suppl 2):70-7.
  19. Szentandrassy N, Harmati G, Barandi L, Simko J, Horvath B, Magyar J, Banyasz T, Lorincz I, Szebeni A, Kecskemeti V, Nanasi PP. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells. Br J Pharmacol. 2011 Jun;163(3):499-509. IF: 4,409
  20. Szebeni A, Szentandrassy N, Pacher P, Simko J, Nanasi PP, Kecskemeti V. Can the electrophysiological action of rosiglitazone explain its cardiac side effects? Curr Med Chem. 2011;18(24):3720-8. IF: 4,859
  21. Nanasi PP, Kecskemeti V. Hot topics in cellular cardiac electrophysiology with potential impact on future drug design. Curr Med Chem. 2011;18(24):3595-6.
  22. Kecskemeti V. Nem kardiovaszkularis gyogyszerek kardiovaszkularis mellekhatasai. Gyogyszeresz Tovabbkepzes. 2011.
  23. Kiss, Mucsi I, Turi S, Szabo A, Kiss I, Szebeni A, Kecskemeti V, Toth M, Lakatos P. A parathormon extraskeletalis hatasai. LAM KID 1. 2011.
  24. Stanulovic V, Zelko R, Kerpel-Fronius S. Predictability of serious adverse reaction alerts for monoclonal antibodies. Int J Clin Pharmacol Ther. 2011 Mar;49(3):185-90. IF: 1,183

 

BOOKS AND BOOKCHAPTERS 

2014.

Gyires K. The role of capsaicin-sensitive afferent nerves in gastric mucosal protection initiated centrally or peripherally under experimental conditions. Capsaicin-sensitive Neuronal Afferentation and the Gastrointestinal Tract: From Bench to Bedside. Chapter 7. pp. 157-184.

2013.

Kalasz H, L. Komsta, M. Waksmundzka-Hajnos, J. Sherma. 2D Planar Chromatography, in Thin-Layer Chromatograpy in Drug Analysis. RC Press-Taylor and Francis New York.

2012.

  1. Knoll J. How Selegiline/(-)-deprenyl Slows Brain Aging. Science e-book.
  2. Gyires K. Analysis of the effect of different neuropeptides in gastric mucosal defense initiated centrally. In: Frontiers of Gastrointestinal Research Vol. 30. Cell/Tisue Injury and Cyto/Organoprotection in the Gastrointestinal Tract. pp. 161-169.
  3. Gyires K. Analysis of the effect of different neuropeptides in gastric mucosal defense initiated centrally. Front Gastrointestinal res.
  4. Papp Gy, Kecskemeti V. Emlekezes Szekeres Laszlora es elnoki idoszakara. Medicina.
  5. Miklya I. Joseph Knoll: How Selegiline((-)-Deprenyl) Slows Brain Aging
    Bentham Science e-Book, Neuropsychopharmacologia Hungarica. pp. 1-163

2011.

Miklya I. The Knoll-concept to decrease the prevalence of Parkinson’s disease. In: David I. Finkelstein (Ed.), Towards new therapies for Parkinson’s Disease. InTech Open Acces Publisher.